The best thing is even if 327 is only as good as soframycin, which seems unlikely as it seems to have outperformed in the animal tests to date, we still have the second shot on target in that there should be no resistance build up with multiple applications. Not only should it outperform but will not add to Mra problems.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.010(3.33%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.0¢ | $25.76K | 82.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13550 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18938 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |